Key result
Despite clinical trial data demonstrating mortality benefits and guideline recommendations, sacubitril-valsartan remains underprescribed for patients with heart failure with reduced ejection fraction.
No takes yet. Share an insight, caveat, or question.
This editorial highlights the underutilization of sacubitril-valsartan in patients with HFrEF despite clinical trial evidence and guideline recommendations.
Packer et al. (2016) conducted an editorial in Heart failure with reduced ejection fraction. Sacubitril-valsartan was evaluated. Despite clinical trial data demonstrating mortality benefits and guideline recommendations, sacubitril-valsartan remains underprescribed for patients with heart failure with reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: